stsa-ex107_49.htm



 

Exhibit 10.7

AMENDMENT NO.4
TO LICENSING AND ASSIGNMENT AGREEMENT

This Amendment No.4 (“Amendment No.4”) to the Licensing and Assignment Agreement by and between Satsuma Pharmaceuticals, Inc. (“Company”) and Shin Nippon Biomedical Laboratories, Ltd. (“SNBL”) of June 30, 2016 (the “Agreement”) is dated as of May 25, 2020 (“Amendment No.4 Effective Date”).


	
 
	
A.
	
Company and SNBL have previously entered into the Agreement, as well as AMENDMENT NO.1 TO LICENSING AND ASSIGNMENT AGREEMENT effective as January 13, 2017, AMENDMENT NO.2 TO LICENSING AND ASSIGNMENT AGREEMENT effective as of April 27, 2017, and AMENDMENT NO.3 TO LICENSING AND ASSIGNMENT AGREEMENT effective as of October 6, 2017.





	
 
	
B.
	
Company and SNBL desire that Exhibit 1.20.2 of the Agreement be amended and restated in its entirety and all other terms and conditions of the Agreement remain in full force and effect.




For good and valuable consideration, Company and SNBL hereby agree as follows:


	
 
	
1.
	
Amendment to the Agreement. 





	
 
	
a.
	
Exhibit 1.20.2 is hereby amended and replaced in its entirety with the following: 




 

 

 





 

 


	
Exhibit 1.20.2

	
 

	
[Transnasal Composition Having Immediate Action and High Absorbability

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Transnasal Composition Having Immediate Action and High Absorbability
	
JP
	
2006-531575 (2005.08.05)
	
4922762 (2012.02.10)

	
US
	
11/660,131 (2005.08.05)
	
8,673,360 (2014.03.18)

	
 
	
 
	
Priority Date: 2004.08.10

	
Preparation for Transnasal Application

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Preparation for Transnasal Application
	
JP
	
2008-551108 (2007.12.25)
	
5415769 (2013.11.22)

	
JP
(Continuation of the above)
	
2013-209951 (2007.12.25)
	
-

	
US
	
12/521,116 (2010.3.25)
	
8,337,817 (2012.12.25)

	
US
(Continuation
of the above)
	
13/649,515 (2012.10.11)
	
10,195,139 (2019.02.05)

	
EP (validated in UK, FR, DE, ES, IT)
	
07860016.0 (2007.12.25)
	
2116264 (2017.09.27)

	
HK
	
10108585.2 (2007.12.25)
	
1142001B (2013.09.06)

	
CN
	
780051041.1 (2007.12.25)
	
200780051041.1

(2013.04.24)

	
Priority Date: 2006.12.26

	
Intranasal Pharmaceutical Compositions with Improved Pharmacokinetics

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Intranasal Pharmaceutical Compositions with Improved Pharmacokinetics
	
US
	
12/780,433 (2010.05.14)
	
9,101,539 (2015.08.11)

	
EP
	
10774745.3 (2010.05.14)
	
-

	
Priority Date: 2009.05.15

	
Intranasal Granisetron and Nasal Applicator

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Intranasal Granisetron and Nasal Applicator
	
US
	
12/848,850 (2010.08.02)
	
8,827,946 (2014.09.09)

	
Priority Date: 2009.07.31




 


	
Intranasal Delivery Devices

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Intranasal Delivery Devices
	
US
	
13/982,461 (2012.01.31)
	
10,071,211/ (2018.09.11)

	
JP
	
2013-551173 (2012.01.31)
	
5960726 (2016.07.01)

	
AU
	
2012212866 (2012.01.31)
	
2012212866 (2017.01.05)

	
CA
	
2825541 (2012.01.31)
	
(Allowed 2020.01.10)

	
CN
	
201280016126.7
(2012.01.31)
	
ZL 2012800161267 (2016.11.30)

	
EP

(GB, DE, FR, ES, IT)
	
12742112.1 (2012.01.31)
	
EP2670462 (2017.11.22)

	
IN
	
6718/DELNP/2013
(2012.01.31)
	
-

	
KR
	
10-2013-7022867
	
 

	
RU
	
2013140383 (2012.01.31)
	
2594244 (2016.08.10)






Page 2of 4

US-DOCS\116938752.2





 


	
Priority Date: 2011.01.31

	
Pharmaceutical Compositions

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Pharmaceutical Compositions
	
US
	
15/668,871 (2017.08.04)
	
-

	
JP
	
2019-506145 (2017.08.04)
	
-

	
EP
	
17784385.1 (2017.08.04)
	
-

	
CN
	
201780049097.7 (2017.08.04)
	
-

	
KR
	
10-2019-7005848 (2017.08.04)
	
 

	
CA
	
3,030,359 (2017.08.04)
	
-

	
AU
	
2017307306 (2017.08.04)
	
-

	
RU
	
2019105698 (2017.08.04)
	
-

	
MX
	
MX/a/2019/001313

(2017.08.04)
	
-

	
BR
	
1120190023712 

(2017.08.04)
	
-

	
IN
	
201817050111 (2017.08.04)
	
-

	
Priority Date: 2016.08.05

	
Nasal Delivery Device for High-Volume Production

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Intranasal Delivery Devices for High-Volume Production
	
US
	
62/563,244 (2017.09.26, provisional)
	
 

	
US
	
16/137,852 (2018.09.21)
	
 

	
The Territory
	
PCT/JP2018/035560 (2018.09.26) and its national applications  claiming priority to PCT/JP2018/035560 in the Field and the Territory
	
 

	
Priority Date: 2017.09.26

	
Medicinal Composition for Nasal Administration

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Medicinal Composition for Nasal Administration
	
JP
	
2002-2201 (2002.01.09)
	
4212019 (2008.11.07)

	
Priority Date: 2002.01.09

	
Compositions for Nasal Administration of Pharmaceuticals

	
Title
	
Country
	
Application No. (Date)
	
Patent No. (Date)

	
Compositions for Nasal Administration of Pharmaceuticals
	
US
	
12/346,537 (2008.12.30)
	
8,435,554 (2013.05.07)

	
 
	
US
	
13/827,859 (2013.03.14)
	
9,138,410 (2015.09.22)

	
 
	
 
	
Priority Date: 2003.02.21




 


	
•
	
Any Patents claiming any Invention(s) disclosed under the SNBL invention disclosure dated November 14, 2016.]




 

 



Page 3of 4

US-DOCS\116938752.2



 

 


	
 
	
2.
	
Miscellaneous.  Capitalized terms used herein and not otherwise defined shall have the meaning given to them in the Agreement.  This Amendment No.4 will be effective for all purposes as of the Amendment No.4 Effective Date.  This Amendment No.4 may be executed in two counterparts, including by facsimile or electronically transmitted copies, each of which will be deemed to be an original, but all of which together will constitute one and the same instrument.




 

IN WITNESS WHEREOF, the Parties have caused this Amendment No.4 to be signed by their respective duly authorized representatives as of the Amendment No.4 Effective Date. 

 


	
SATSUMA Pharmaceuticals, inc.
	
 
	
Shin Nippon Biomedical Laboratories, Ltd.

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
/s/ John Kollins
	
 
	
 
	
By:
	
/s/ Shunji Haruta
	
 
	
 

	
 
	
 
	
 
	
 
	
 

	
Printed Name: 
	
John Kollins
	
 
	
Printed Name: 
	
Shunji Haruta

	
 
	
 
	
 
	
 
	
 

	
Title:
	
President & CEO
	
 
	
Title:
	
TR Company Vice President




 

Page 4of 4

US-DOCS\116938752.2